- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02346578
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
September 8, 2021 updated by: Taro Iguchi, MD, PHD
Multicenter, Prospective, Randomised and Comparative Study of AA Therapy and Early Administrating Enzalutamide in Participants With CRPC Previously Treated With CAB Therapy Using Bicalutamide.
The objective of this study is to compare the efficacy and safety of enzalutamide or alternative AA therapy in CRPC participants who were previously treated with a combined androgen blockade therapy which included bicalutamide (Bic-CAB).
Efficacy and safety of enzalutamide and alternative AA therapy will be evaluated, and effective therapy against CRPC after treatment with Bic-CAB will be investigated.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
104
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Osaka, Japan
- Osaka City University Graduate School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Testosterone of less than 50 ng/dL
- Participants who was detected of disease progression on image or relapse of PSA (All PSA values measured 3 time at least one week interval are consecutively increased and final value is 2 ng/mL or more. If third value is not higher than second one, fourth measurement will be undertaken and its value must be higher than second one.)
- Participants who relapsed after CAB with bicalutamide
- Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1
- Aged 20 years or older
- Participants who provided written informed consent
Exclusion Criteria:
- Any prior treatment with enzalutamide, flutamide, abiraterone or chemotherapy, except for neoadjuvant therapy
- With active double cancer
- Any prior treatment with bicalutamide within 6 weeks
- Participants who received systemic biological therapy (except for existing approved drug for bone or treatment with luteinizing hormone-releasing hormone (LHRH) analogue) or received treatment with other antitumor agent for prostate cancer
- With serious complication
- History of hypersensitivity to enzalutamide or any other excipient of enzalutamide
- History of hypersensitivity to flutamide-containing agent
- With liver dysfunction
- Participants who are considered as inadequate by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Enzalutamide
Enzalutamide 160 mg administered orally once a day as four 40-mg soft capsules
|
|
ACTIVE_COMPARATOR: Flutamide
Flutamide 125 mg administered orally three times a day as one tablet after meal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of participants whose prostate specific antigen (PSA) decreased 50 percent or more at month 3
Time Frame: Month 3
|
Month 3
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of participants whose PSA decreased 50 percent or more at month 6
Time Frame: Month 6
|
Month 6
|
Percentage of participants who showed disease progression at month 3
Time Frame: Month 3
|
Month 3
|
Percentage of participants who showed disease progression at month 6
Time Frame: Month 6
|
Month 6
|
PSA progression-free survival (PFS)
Time Frame: Up to 39 months
|
Up to 39 months
|
QOL measured by functional assessment of cancer therapy-prostate (FACT-P)
Time Frame: Up to 39 months
|
Up to 39 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Iguchi T, Tamada S, Kato M, Yasuda S, Yamasaki T, Nakatani T. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study). BMC Cancer. 2019 Apr 11;19(1):339. doi: 10.1186/s12885-019-5526-3.
- Iguchi T, Tamada S, Kato M, Yasuda S, Machida Y, Ohmachi T, Ishii K, Iwata H, Yamamoto S, Kanamaru T, Morimoto K, Hase T, Tashiro K, Harimoto K, Deguchi T, Adachi T, Iwamoto K, Takegaki Y, Nakatani T. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study. Int J Clin Oncol. 2020 Mar;25(3):486-494. doi: 10.1007/s10147-019-01554-3. Epub 2019 Sep 28.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (ACTUAL)
September 30, 2018
Study Completion (ACTUAL)
January 22, 2019
Study Registration Dates
First Submitted
January 15, 2015
First Submitted That Met QC Criteria
January 20, 2015
First Posted (ESTIMATE)
January 27, 2015
Study Record Updates
Last Update Posted (ACTUAL)
September 16, 2021
Last Update Submitted That Met QC Criteria
September 8, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Androgen Antagonists
- Flutamide
Other Study ID Numbers
- OCUU-CRPC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Castration-resistant Prostate Cancer
-
Nuvation Bio Inc.WithdrawnProstate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic NeoplasmsUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Astellas Pharma IncPfizerCompletedCastration-resistant Prostate CancerJapan
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Translational Research Center for Medical Innovation...CompletedCastration Resistant Prostate Cancer (CRPC)
Clinical Trials on Enzalutamide
-
ESSA PharmaceuticalsRecruitingProstate CancerCanada, United States, Australia
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedProstate Cancer | Pharmacokinetics of EnzalutamideUnited States
-
Groupe Hospitalier Pitie-SalpetriereCompletedEpilepsy | Prostate Cancer | Neuropathy | EncephalopathyFrance
-
Radboud University Medical CenterActive, not recruitingProstatic Neoplasms, Castration-ResistantNetherlands
-
Fundación Canaria de Investigación SanitariaHospital Universitario de CanariasUnknown
-
Translational Research Center for Medical Innovation...Kagawa UniversityCompleted
-
Andreas JosefssonGöteborg University; Umeå University; Sahlgrenska University Hospital, Sweden; Sundsvall... and other collaboratorsTerminated
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
-
Macquarie University, AustraliaUnknown
-
National Cancer Institute (NCI)Terminated